Similar Papers

Paper Title
Journal
Date
Author
Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate
Bin Zhang ... Ravi Bhatia
Cancer Cell | VOL. 17
Bin Zhang, et. al.Bin Zhang ... Ravi Bhatia
01 May 2010
Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3‐year follow‐up
Massimo Breccia ... Vittorio Del Fabro
American Journal of Hematology | VOL. 85
Massimo Breccia, et. al.Massimo Breccia ... Vittorio Del Fabro
21 Apr 2010
Imatinib as the first‐line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials?
Daniela Zackova ... Filip Razga
American Journal of Hematology | VOL. 86
Daniela Zackova, et. al.Daniela Zackova ... Filip Razga
15 Feb 2011
The treatment of chronic myeloid leukaemia--much still to be achieved.
J M Goldman
Journal of internal medicine | VOL. 235
J M GoldmanJ M Goldman
01 Apr 1994
View more papers

More From: American Journal of Hematology

Paper Title
Journal
Date
Author
Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes toContemporary Therapies.
Jayastu Senapati ... Courtney D Dinardo
American journal of hematology | VOL. -
Jayastu Senapati, et. al.Jayastu Senapati ... Courtney D Dinardo
08 Feb 2025
It's More Than Complex: Further Insights Into TP53 in MPN.
Nico Gagelmann ... Nicolaus Kröger
American journal of hematology | VOL. -
Nico Gagelmann, et. al.Nico Gagelmann ... Nicolaus Kröger
08 Feb 2025
Issue Information
-
American Journal of Hematology | VOL. -
--
07 Feb 2025
Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study.
Samuel Yamshon ... Loretta J Nastoupil
American journal of hematology | VOL. -
Samuel Yamshon, et. al.Samuel Yamshon ... Loretta J Nastoupil
07 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.